Circulating extracellular vesicles are monitoring biomarkers of anti-PD1 response and enhancer of tumor progression and immunosuppression in metastatic melanoma.
Anti-PD1 resistance
Extracellular vesicles
Metastatic melanoma
Predictor of anti-PD1 response
Journal
Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647
Informations de publication
Date de publication:
28 Sep 2023
28 Sep 2023
Historique:
received:
16
06
2023
accepted:
22
08
2023
medline:
29
9
2023
pubmed:
28
9
2023
entrez:
27
9
2023
Statut:
epublish
Résumé
Clinical drawback in checkpoint inhibitors immunotherapy (ICI) of metastatic melanoma (MM) is monitoring clinical benefit. Soluble forms of PD1(sPD1) and PD-L1(sPD-L1) and extracellular vesicles (EVs) expressing PD1 and PD-L1 have recently emerged as predictive biomarkers of response. As factors released in the blood, EVs and soluble forms could be relevant in monitoring treatment efficacy and adaptive resistance to ICI. We used pre-therapy plasma samples of 110 MM patients and longitudinal samples of 46 patients. Elisa assay and flow cytometry (FCM) were used to measure sPD-L1 and sPD1 concentrations and the percentage of PD1 The concentrations of sPD1 and sPD-L1 in pre-treatment and longitudinal samples did not correlate with anti-PD1 response, instead only tumor-derived PD1 Collectively, we suggest that the detection of tumor-derived PD1 + EVs may represent a useful tool for monitoring the response to anti-PD1 and a role for EVs shed by tumor and immune cells in promoting tumor progression and immune dysfunction.
Sections du résumé
BACKGROUND
BACKGROUND
Clinical drawback in checkpoint inhibitors immunotherapy (ICI) of metastatic melanoma (MM) is monitoring clinical benefit. Soluble forms of PD1(sPD1) and PD-L1(sPD-L1) and extracellular vesicles (EVs) expressing PD1 and PD-L1 have recently emerged as predictive biomarkers of response. As factors released in the blood, EVs and soluble forms could be relevant in monitoring treatment efficacy and adaptive resistance to ICI.
METHODS
METHODS
We used pre-therapy plasma samples of 110 MM patients and longitudinal samples of 46 patients. Elisa assay and flow cytometry (FCM) were used to measure sPD-L1 and sPD1 concentrations and the percentage of PD1
RESULTS
RESULTS
The concentrations of sPD1 and sPD-L1 in pre-treatment and longitudinal samples did not correlate with anti-PD1 response, instead only tumor-derived PD1
CONCLUSION
CONCLUSIONS
Collectively, we suggest that the detection of tumor-derived PD1 + EVs may represent a useful tool for monitoring the response to anti-PD1 and a role for EVs shed by tumor and immune cells in promoting tumor progression and immune dysfunction.
Identifiants
pubmed: 37759291
doi: 10.1186/s13046-023-02808-9
pii: 10.1186/s13046-023-02808-9
pmc: PMC10538246
doi:
Substances chimiques
B7-H1 Antigen
0
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
251Subventions
Organisme : Regione Puglia
ID : Tecnopolo per la Medicina di Precisione (CUP B84I18000540002)
Organisme : Ministero della Salute
ID : RC 2022-2024: Identificazione di fattori circolanti per la diagnosi
Organisme : Ministero della Salute
ID : prognosi e/o predizione della risposta alle terapie in patologie tumorali solide
Organisme : Alleanza Contro il Cancro
ID : Medicina personalizzata: Allestimento di biobanche e di modelli colturali organotipici da pazienti con melanoma per l'identificazione di nuovi marcatori prognostici e la realizzazione di saggi predittivi della risposta del paziente alla terapia
Organisme : Alleanza Contro il Cancro
ID : ACC Preclinical research platform for precision oncology-cod WFR: RCR-2022-23682287
Informations de copyright
© 2023. Italian National Cancer Institute ‘Regina Elena’.
Références
Mol Cancer. 2022 Jan 18;21(1):20
pubmed: 35042524
Lancet. 2017 Oct 21;390(10105):1853-1862
pubmed: 28822576
Cell Metab. 2021 Oct 5;33(10):2040-2058.e10
pubmed: 34559989
Cancer Cell. 2016 Aug 8;30(2):243-256
pubmed: 27505671
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
Ann Endocrinol (Paris). 2000 Feb;61(1):70-4
pubmed: 10790595
J Hematol Oncol. 2019 Jul 12;12(1):76
pubmed: 31300030
Immunobiology. 2010 Sep-Oct;215(9-10):796-803
pubmed: 20692534
Oncotarget. 2018 Apr 17;9(29):20826-20837
pubmed: 29755693
Nat Cell Biol. 2015 Jun;17(6):816-26
pubmed: 25985394
J Invest Dermatol. 2009 Apr;129(4):1016-25
pubmed: 18843292
J Immunother Cancer. 2021 May;9(5):
pubmed: 33972390
J Extracell Vesicles. 2019 Apr 01;8(1):1596016
pubmed: 30988894
J Hepatol. 2011 Oct;55(4):936-8
pubmed: 21708198
Int J Mol Sci. 2018 Jul 24;19(8):
pubmed: 30042333
Lancet Oncol. 2019 Sep;20(9):1239-1251
pubmed: 31345627
J Immunol. 2009 Oct 1;183(7):4705-14
pubmed: 19752225
Int J Mol Sci. 2020 Mar 26;21(7):
pubmed: 32225076
Front Immunol. 2020 May 07;11:784
pubmed: 32457745
Int Immunopharmacol. 2020 Jan;78:106113
pubmed: 31841754
Exp Cell Res. 2014 Feb 15;321(2):240-7
pubmed: 24384475
Oncoimmunology. 2021 May 25;10(1):1926762
pubmed: 34104542
Cancers (Basel). 2021 Dec 21;14(1):
pubmed: 35008170
BMC Cancer. 2017 Mar 24;17(1):215
pubmed: 28340565
Mol Cancer Ther. 2019 Oct;18(10):1844-1851
pubmed: 31363009
EBioMedicine. 2021 May;67:103365
pubmed: 33971402
Nat Methods. 2017 Feb 28;14(3):228-232
pubmed: 28245209
Curr Protoc Cell Biol. 2006 Apr;Chapter 3:Unit 3.22
pubmed: 18228490
Clin Cancer Res. 2018 Mar 15;24(6):1260-1270
pubmed: 29127120
Trends Cancer. 2018 Jun;4(6):445-459
pubmed: 29860988
Mol Cancer Ther. 2022 Jul 5;21(7):1067-1075
pubmed: 35545008
Sci Rep. 2017 Jun 16;7(1):3698
pubmed: 28623253
IUBMB Life. 2010 Aug;62(8):611-7
pubmed: 20681025
Front Nutr. 2021 Jan 13;7:612397
pubmed: 33521038
J Clin Oncol. 2022 Jan 10;40(2):127-137
pubmed: 34818112
J Vis Exp. 2014 Jun 01;(88):
pubmed: 24962652
J Interferon Cytokine Res. 2009 Jun;29(6):313-26
pubmed: 19441883
J Biol Regul Homeost Agents. 2011 Apr-Jun;25(2):239-47
pubmed: 21880213
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
NPJ Precis Oncol. 2022 Jun 21;6(1):42
pubmed: 35729210
Cell Mol Life Sci. 2021 Mar;78(6):3057-3072
pubmed: 33237352
Cancers (Basel). 2021 May 20;13(10):
pubmed: 34065529
J Immunother Cancer. 2020 May;8(1):
pubmed: 32457125
Immunotherapy. 2017 Mar;9(4):347-360
pubmed: 28303764
Cancers (Basel). 2022 Jul 09;14(14):
pubmed: 35884403
PLoS One. 2018 Nov 6;13(11):e0206942
pubmed: 30399176
J Immunother Cancer. 2021 Jan;9(1):
pubmed: 33408092
Int J Mol Sci. 2020 Jul 23;21(15):
pubmed: 32718103
Sci Adv. 2020 Feb 26;6(9):eaax3223
pubmed: 32133394
Pharmacol Res. 2022 Aug;182:106323
pubmed: 35752358
Anticancer Res. 2010 Feb;30(2):345-54
pubmed: 20332438
Cell Commun Signal. 2022 Sep 12;20(1):141
pubmed: 36096820